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care health plan; patientswere followed until death, disenrollment from the health
plan, or 12/31/2008. Health care costs in the 24 months prior to death/end of fol-
low-up were calculated, divided into 4-month periods to assess trends over time.
Chi-square statistics were used to compare patients who died vs. those alive at the
end of the study on health care costs, comorbidity, clinical, and demographic
characteristics. RESULTS: 260 CRPC patients died, with 2304 patients alive at the
end of the study (mean age 73.99 vs. 72.63 years, p0.035). 2 years prior to death/
end of follow-up, comorbidity scores were similar and mean total costs per
4-month period were not significantly different for patients who died vs. those
alive ($8,292 vs. $6,809, p0.060). Health care costs increased prior to death, with
the sharpest increase in the last 4-months of life with mean costs roughly tripling
(from $15,185 to $44,203). For patients who did not die, mean total costs increased
by one-third in each 4-month period, from$6,809 to $13,170 at the end of follow-up.
CONCLUSIONS: Although costs were initially similar for CRPC patients who died
compared to patients alive at study end, patients who died had significantly larger
increases in costs over the 2-year period, with the sharpest increase in the last year
prior to death.
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OBJECTIVES: 7,538 new cases of SCCHN were diagnosed in 2006 and 2,594 deaths
reported in 2007 in the UK. For patients with resectable SCCHN surgical resection
followed by postoperative radiation therapy remains a common treatment ap-
proach. For locoregional disease control chemotherapy is also an important treat-
ment component. METHODS: This retrospective analysis was based on inpatient
and outpatient records extracted from Hospital Episode Statistic database. SCCHN
patients with resection of oral cavity, pharynx or larynx between 2003-07-01 and
2008-03-31 were followed for at least one year (max. of 5 years) from the surgery
date. RESULTS: There were 38,460 patients diagnosed with SCCHN in the dataset.
11,403 patients met the inclusion criteria for the study. Mean age was 63.2 years
and 69.8% were male. Mean length of follow-up was 31.0 months. In the first year,
mean length of hospitalizationwas 21.6 days andmeannumber of outpatient visits
was 4.2. Mean number of reconstructive and secondary surgeries per patient was
0.32 and 0.14, respectively in the first year. Mean number of radiotherapy and
chemotherapy sessions per patient was both 0.45 in the first year. Total costs of
post-operative healthcare utilization in the patient cohort was £249.4 million over
5 years with 90% (£225.5 million) occurring within the first year. Mean cost was
£19,778 for the first year and £1477, £847, £653 and £455 for years 2-5. Inpatient care
costs accounted for 96% of total costs with hospitalization contributing to 85% of
these costs.CONCLUSIONS:Given limited outpatient data in theHES, radiotherapy
and chemotherapy utilization and costs in the outpatient setting are likely to be
underestimated. However, results still indicate that treatment of resected SCCHN
in the UK is associated with significant healthcare utilization and costs. This sug-
gests the need for new therapies that could improve outcomes and reduce the
economic burden.
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OBJECTIVES: Out-of-pocket (OOP) medical expenditures of families may pose a
financial burden, particularly to the seriously ill. The objective of this study was to
analyze financial burden among patients with three common cancers: breast can-
cer (BC), colorectal cancer (CRC), and lung cancer (LC). METHODS: This study in-
cluded respondents in the US Medical Expenditure Panel Survey who had 1 BC
(ICD-9-CM 174.xx), CRC (ICD-9-CM 153.xx, 154.xx), or LC (ICD-9-CM 162.xx) diagno-
sis between 1996 and 2007. Matched comparison cohorts (without cancer) were
constructed for each cancer type, based on age, payor, sex, race and region. All
years of datawere pooled andweighted to create nationally representative average
annual estimates reported in 2009 USD. OOP family medical expenditures (not
including premiums), and family income were analyzed. Families were defined as
having a highOOP burden if their OOP expenditures exceeded 10% of annual family
income (5% if low income). RESULTS: 1,849 patients with cancer were identified
(1,083 BC, 467 CRC, 299 LC). Total OOP expenditures averaged $3,400 - $4,400 for
cancer patients versus $2,100 - $2,700 for controls. Overall, 31-37% of cancer pa-
tients had high OOP burden (31% BC, 37% CRC, 35% LC), compared to about a
quarter of matched comparison patients. Among those under age 65, 16-30% of
privately insured hadhigh burden. Among those 65,moreMedicare-only patients
had high burden (48-53%) compared to those with Medicare plus other insurance
(29-36%). CONCLUSIONS: Over a third of cancer patients have OOP expenditures
greater than 5-10% of their household income. Privately insured patients appear
least likely to have high burden while publicly insured appear most likely. To
ensure that cancer patients can adequately access needed medical care, explora-
tion of how US health reform or other policy options could reduce this financial
burden is warranted.
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OBJECTIVES:Monoclonal antibodies improve treatment outcomes in patients with
metastatic colorectal cancer (mCRC); they have distinct and known safety profiles
that may be associated with toxicities requiring hospitalization, which likely fur-
ther impact cost of patient care. The objective of this study was to determine
hospital costs of these events.METHODS: From the PHARMO Record Linkage Sys-
tem, including drug dispensing and hospitalization records of approximately 3.2
million residents in The Netherlands, all patients with a primary or secondary
hospital discharge code for CRC and distant metastasis between 2000 and 2008
were defined as patients with mCRC. The first discharge diagnosis defining metas-
tases served as the index date. Patients were followed from index date until end of
data collection, death, or end of study period, whichever occurred first. Main out-
comes for each identified event were length of stay (days) and costs per hospital
admission (€). All results are presented descriptively. RESULTS: Among 2,964 pa-
tients with mCRC identified, 271 hospital events occurred during a median fol-
low-up of 24 months. The longest mean ( SD) lengths of stay per hospital admis-
sion were for stroke (16 ( 33) days) and arterial thromboembolism (ATE) (14 ( 21)
days), followed by wound healing complications (WHC), acute myocardial infarc-
tion (AMI), congestive heart failure (CHF), and neutropenia (all 9 days with SD 5 to
15). Highest mean ( SD) costs per admission were observed for stroke (€13,500 (
€28,800)), ATE (€13,300 ( €18,800)), andWHC (€10,800 ( €20,500)), followed by AMI
((€9,000 ( €7,300)), neutropenia (€7,900 ( €4,400)), and CHF (€7,700 ( €6,300)).
Lowest mean ( SD) costs were for dermatological toxicity (€5,400 ( €5,200)) and
hypertension (€4,100 ( €2,800)). CONCLUSIONS: Inpatient costs for events in pa-
tients with mCRC are considerable and vary greatly. Such data are valuable to the
pharmacoeconomic evaluations of newer treatments in patients with mCRC.
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OBJECTIVES:To study themedical expenditure of insured patientswith cancer and
its influence factors, to analyze the utilization of pharmaceuticals, treatment-seek-
ing behavior and the relationship between the medical expenditure and payment
patterns ofmedical insurance.METHODS:This study involved 5351 cancer cases in
3 municipalities (Beijing, Shanghai, Chongqing) and 5 province-capital cities (She-
nyang, Fuzhou, Jinan,Zhengzhou, Xining).The actual claim data of their medical
expenditure and medical care utilization in 2008 were collected. Descriptive anal-
ysis and multivariate linear regression analysis were applied. RESULTS: 1) Outpa-
tient’s annual medical expenditure per head was US$802 and inpatient’s annual
medical expenditure per head was US$6200. Although the basic medical insurance
(BMI) fund covered about 70% of the expenditure, the patients’ economic burden is
still heavy. 2) Western medicine cost accounted for 44% to 60% of the inpatients’
medical expenditure in various cities. Cytotoxic drug usage accounted for over 80%
of the anti-tumor drugs. 3) The proportion of the patients who sought outpatient
and inpatient treatment in the third level hospitals was 81% and 74%, respectively.
4) Multivariate linear regression analysis showed that themain influence factors of
inpatients’ medical expenditure include medical insurance payment pattern, hos-
pital level, category of cancer, gender, length of stay in hospital, and medical in-
surance type. When all factors other than payment pattern were set to be control
parameters, inpatient’s annual medical expenditure per head under flat rate pay-
ment was US$348 lower than that under fee-for service. CONCLUSIONS: Medical
expenditure causes heavy burden for cancer patients and the BMI fund. Flat rate
payment has proved to be more effective in expenditure control compared with
fee-for service. To keep the fund safe and running effectively, it is necessary to
adjust present payment patterns and set rational payment standard to encourage
medical care providers to control the expenditure actively.
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OBJECTIVES: To assess healthcare expenditures, disability days, and resource uti-
lization in persons with cancer that were employed within large and small organi-
zations in the United States. METHODS: This retrospective database analysis uti-
lized 2007 Agency for Healthcare Research and Quality (AHRQ) Medical
Expenditure Panel Survey (MEPS) public-use data. Inclusion criteria included age
18 years, any diagnosis of malignant neoplasms (including both new cases and
those continuing treatment), and employment within either large or small organi-
zations (500 or 500 employees, respectively). Regression analyses were per-
formed via gamma or negative binomial generalized linearmodels for outcomes of
total direct healthcare expenditures, number of disability days, and summed re-
source utilization (outpatient visits, emergency department visits, hospitaliza-
tions) after controlling for predominant cancer types and other factors including
demographics (age, sex, race, education, region, income, residence), insurance cov-
erage, employer size, perceived health status, secondary malignancies, and the
D’Hoore-Charlson Comorbidity Index. To provide national estimates, all results
were weighted and used standard errors (SE) calculated via Taylor-series
approaches. RESULTS: Overall, 3.86 million employed adults in the US had new or
continued cases of cancer in 2007, averaging 54.0 (SE0.9) years of age, 9.3 (SE1.8)
disability days, and $15,365 (SE2921) in expenditures. Mostwere employedwithin
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